CN113143993A - Traditional Chinese medicine preparation for coronary stent postoperative blood stasis and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for coronary stent postoperative blood stasis and preparation method thereof Download PDFInfo
- Publication number
- CN113143993A CN113143993A CN202110451611.8A CN202110451611A CN113143993A CN 113143993 A CN113143993 A CN 113143993A CN 202110451611 A CN202110451611 A CN 202110451611A CN 113143993 A CN113143993 A CN 113143993A
- Authority
- CN
- China
- Prior art keywords
- decoction
- preparation
- fine powder
- blood stasis
- decompressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 title claims abstract description 11
- 210000004369 blood Anatomy 0.000 title claims abstract description 11
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title claims description 13
- 239000000843 powder Substances 0.000 claims abstract description 9
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 6
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 5
- 229920002261 Corn starch Polymers 0.000 claims abstract description 3
- 229920001353 Dextrin Polymers 0.000 claims abstract description 3
- 239000004375 Dextrin Substances 0.000 claims abstract description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 3
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 3
- 239000008120 corn starch Substances 0.000 claims abstract description 3
- 235000019425 dextrin Nutrition 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 206010041956 Stasis syndrome Diseases 0.000 abstract description 2
- 208000005634 blind loop syndrome Diseases 0.000 abstract description 2
- 239000002075 main ingredient Substances 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicinal preparation for coronary artery stent postoperative blood stasis syndrome comprises Saviae Miltiorrhizae radix, Notoginseng radix, and folium Ginkgo as main ingredients, and its preparation method comprises: firstly, 166.5g of pseudo-ginseng is cut off, water is added for decoction twice, each time, 13320g of water is added, each time, the decoction is carried out for 1.5 hours, the decoction liquid after the decoction twice is combined, the combined decoction liquid is filtered to obtain filtrate, the filtrate is decompressed and concentrated to the relative density of 1.20-1.25, thick paste with the temperature of 60 ℃ is obtained, and the thick paste is decompressed, dried and crushed into fine powder; and secondly, adding 666g of salvia miltiorrhiza and 499.5g of ginkgo leaves into the fine powder obtained in the first step, adding dextrin and corn starch, uniformly mixing, granulating, drying and preparing into 1000g of the fine powder.
Description
Technical Field
The invention relates to a traditional Chinese medicine preparation for coronary stent postoperative blood stasis and a preparation method thereof, belonging to the field of medicines.
Background
Since Gruentzig performed the 1 st PTCA operation in the world in 1977, PTCA is rapidly accepted by patients due to its small trauma and ability to rapidly and effectively resolve stenosis and occlusion of coronary arteries. Since then, the PCI technology based on PTCA and intracoronary stent implantation is rapidly developed, and PCI has become an important means for treating coronary heart disease at present. In particular, the advent of Drug Eluting Stents (DES) has led to a significant reduction in the incidence of restenosis events, pushing the development of PCI surgery to a new height, and interventional cardiology has become the fastest growing discipline in cardiology. However, interventional therapy does not solve all the problems of patients with coronary heart disease, and restenosis after stent implantation and acute, subacute and late stent thrombosis severely restrict the long-term efficacy after PCI. The intervention treatment focuses on local intervention, and the main reasons influencing the long-term curative effect are insufficient overall attention and the limitation of postoperative oral medicines.
Researches in recent years show that the traditional Chinese medicine can comprehensively act on a plurality of pathological links after stent operation from integral intervention, and has obvious advantages of preventing restenosis in the stent, improving the cardiac function of patients and improving the life quality of the patients. Although the research of preventing and intervening restenosis after cardiac stenting by traditional Chinese medicine is started later, the relevant experimental research and clinical observation results show that the traditional Chinese medicine has good application prospect. At present, the research of traditional Chinese medicine has already elucidated some etiology, pathology and treatment mechanism of restenosis from the aspect of molecular gene level, and is a major breakthrough in the field.
Disclosure of Invention
In order to solve the existing problems, the invention provides a traditional Chinese medicine preparation for coronary stent postoperative blood stasis and a preparation method thereof.
The technical scheme adopted by the invention for solving the technical problem is as follows:
a traditional Chinese medicine preparation for coronary stent postoperative blood stasis and a preparation method thereof are characterized by comprising a device cover, the device cover is provided with an inlet and an outlet, the device cover is detachably and hermetically connected with the shell, the shell is cylindrical, the filter box is arranged in the shell, a gap is arranged between the filter box and the shell, the side wall of the filter box is provided with a plurality of holes, the activated carbon layer is tightly attached to the inner wall of the filter box, the fiber membrane filter layer is arranged in a container, an ion exchange resin layer is arranged around the outside of the fiber membrane filter layer, filter cotton is arranged at the bottom of the container, the sealing ring is arranged above the container, the fiber membrane filtering layer is clamped between the sealing ring and the filter cotton, the bottom of the container is hollow, the top end of the container is communicated with the shell, the shell is communicated with the outlet on the device cover, a gap is formed between the container and the activated carbon layer, and a gap is formed between the bottom of the container and the bottom of the shell 210.
The invention has the following beneficial effects: promoting blood circulation, dredging collaterals, removing blood stasis, nourishing heart, and can be used for treating thoracic obstruction and cardiodynia caused by coronary heart disease and coronary artery support postoperative heart vessel blood stasis, with symptoms of chest distress or chest pain, pain induced shoulder and back, pain location, nocturnal emission, short breath, aversion to cold, debilitation, purple and dark lip and tongue, thin tongue coating, and thready and unsmooth pulse or intermittent pulse.
Detailed Description
The present invention will now be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all embodiments of the invention are shown. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
A Chinese medicinal preparation for coronary artery stent postoperative blood stasis syndrome comprises Saviae Miltiorrhizae radix, Notoginseng radix, and folium Ginkgo as main ingredients, and its preparation method comprises:
firstly, 166.5g of pseudo-ginseng is cut off, water is added for decoction twice, each time, 13320g of water is added, each time, the decoction is carried out for 1.5 hours, the decoction liquid after the decoction twice is combined, the combined decoction liquid is filtered to obtain filtrate, the filtrate is decompressed and concentrated to the relative density of 1.20-1.25, thick paste with the temperature of 60 ℃ is obtained, and the thick paste is decompressed, dried and crushed into fine powder;
and secondly, adding 666g of salvia miltiorrhiza and 499.5g of ginkgo leaves into the fine powder obtained in the first step, adding dextrin and corn starch, uniformly mixing, granulating, drying and preparing into 1000g of the fine powder.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (2)
1. A Chinese medicinal preparation for treating coronary artery stent postoperative blood stasis is characterized by mainly comprising Saviae Miltiorrhizae radix, Notoginseng radix, and folium Ginkgo.
2. A preparation method of a traditional Chinese medicine preparation for coronary stent postoperative blood stasis is characterized in that in the first step, 166.5g of pseudo-ginseng is cut off, water is added for decoction twice, each time, 13320g of water is added, each time, the decoction is carried out for 1.5 hours, the decoction liquids after the two times of decoction are combined, the combined decoction liquid is filtered to obtain filtrate, the filtrate is decompressed and concentrated to the relative density of 1.20-1.25, thick paste with the temperature of 60 ℃ is obtained, and the thick paste is decompressed, dried and crushed into fine powder; and secondly, adding 666g of salvia miltiorrhiza and 499.5g of ginkgo leaves into the fine powder obtained in the first step, adding dextrin and corn starch, uniformly mixing, granulating, drying and preparing into 1000g of the fine powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110451611.8A CN113143993A (en) | 2021-04-26 | 2021-04-26 | Traditional Chinese medicine preparation for coronary stent postoperative blood stasis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110451611.8A CN113143993A (en) | 2021-04-26 | 2021-04-26 | Traditional Chinese medicine preparation for coronary stent postoperative blood stasis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113143993A true CN113143993A (en) | 2021-07-23 |
Family
ID=76871092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110451611.8A Pending CN113143993A (en) | 2021-04-26 | 2021-04-26 | Traditional Chinese medicine preparation for coronary stent postoperative blood stasis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113143993A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115919928A (en) * | 2022-11-24 | 2023-04-07 | 吉林省寰宇济民科技有限公司 | Sanshen collaterals-dredging quick-acting dropping pill and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247434A (en) * | 2010-05-20 | 2011-11-23 | 云南楚雄天利药业有限公司 | Przewalsk sage root blood activating medicine and preparation method thereof |
| CN103191187A (en) * | 2012-01-06 | 2013-07-10 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Uses of different positions of Salvia miltiorrhiza Bunge and Panax Notoginseng and combinations thereof in smooth muscle cell proliferation inhibition and coronary artery restenosis control |
| CN105796625A (en) * | 2014-12-31 | 2016-07-27 | 北京北大维信生物科技有限公司 | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof |
-
2021
- 2021-04-26 CN CN202110451611.8A patent/CN113143993A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247434A (en) * | 2010-05-20 | 2011-11-23 | 云南楚雄天利药业有限公司 | Przewalsk sage root blood activating medicine and preparation method thereof |
| CN103191187A (en) * | 2012-01-06 | 2013-07-10 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Uses of different positions of Salvia miltiorrhiza Bunge and Panax Notoginseng and combinations thereof in smooth muscle cell proliferation inhibition and coronary artery restenosis control |
| CN105796625A (en) * | 2014-12-31 | 2016-07-27 | 北京北大维信生物科技有限公司 | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof |
Non-Patent Citations (5)
| Title |
|---|
| 丁寻实，等: "银杏叶胶囊联合通脉口服液治疗冠心病PCI术后再狭窄的疗效观察", 《现代药物与临床》 * |
| 孔俊虹，等: "活血化瘀法防治冠心病PCI术后再狭窄", 《浙江中西医结合杂志》 * |
| 孟庆: "活血化瘀方对PCI后血瘀证干预的临床研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 李文青，等: "中西医结合干预冠状动脉支架内再狭窄临床研究", 《中国煤炭工业医学杂志》 * |
| 黄伟强，等: "复方丹参滴丸、普罗布考对动脉损伤后内膜增殖与血管重塑的影响", 《广西医科大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115919928A (en) * | 2022-11-24 | 2023-04-07 | 吉林省寰宇济民科技有限公司 | Sanshen collaterals-dredging quick-acting dropping pill and preparation method and application thereof |
| CN115919928B (en) * | 2022-11-24 | 2023-11-10 | 中山市康腾医疗高科研究有限公司 | Quick-acting dripping pills of three ginseng for dredging collaterals, its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113143993A (en) | Traditional Chinese medicine preparation for coronary stent postoperative blood stasis and preparation method thereof | |
| CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
| CN104840687A (en) | Pharmaceutical preparation for treating pelvic inflammation | |
| CN102106904A (en) | Method for preparing pharmaceutical preparation for treating palpitation and cardiodynia and quality control method thereof | |
| CN103908490A (en) | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof | |
| CN1088998C (en) | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method | |
| CN1294961C (en) | Oral liquid for curing myocardial ischemia and process for preparing the same | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN105535890B (en) | A kind of pharmaceutical composition and preparation method thereof for treating cardiovascular disease | |
| CN106565849B (en) | A kind of preparation method and applications of aizoon stonecrop polysaccharide | |
| CN100391484C (en) | Medicine for treating cardio-cerebrovascular disease | |
| CN114767794B (en) | Traditional Chinese medicine for treating arterial plaque | |
| CN104147168B (en) | A kind of Chinese medicine for treating pressure ulcer | |
| CN106822205A (en) | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition | |
| CN110934980A (en) | Traditional Chinese medicine formula and application thereof | |
| CN117159645A (en) | Anti-tumor traditional Chinese medicine composition | |
| CN112915185A (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN104825682A (en) | Traditional Chinese medicine for treatment of coronary heart disease angina pectoris | |
| CN1478501A (en) | Chinese medicinal composition for treating coronary heart disease and angina pectoris and its preparation process | |
| CN1202845C (en) | Medicine for treating prostatosis and its prepn | |
| CN100391485C (en) | Medicine for treating diabetes and its preparation method | |
| CN105727044A (en) | Drug for treating obstruction of qi in the chest | |
| RU2185843C2 (en) | Method for treating diseases of liver and biliferous ducts | |
| CN103006868A (en) | Traditional Chinese medicine composition for treating Behcet diseases | |
| CN102232997A (en) | Medicament for treating myocardial ischemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210723 |